BOSTON — On the first Monday in March, Michel Vounatsos, chief executive of the drug company Biogen, appeared in good spirits. The company’s new Alzheimer’s drug was showing promise after years of setbacks. Revenues had never been higher.
“The smartest people in health care and drug development — and they were completely oblivious to the biggest thing that was about to shatter their world,” said John Carroll, editor of Endpoints News, which covers the biotech industry. Responding to questions from The New York Times, Vounatsos refused to say even whether he had been tested for COVID-19.
Founded in 1978 and based near Boston, Biogen helped pioneer the biotechnology industry, specializing in multiple sclerosis drugs. The company is best known now for its work on a promising treatment for Alzheimer’s. Although some other companies canceled international meetings around that time, Biogen never discussed doing so. The outbreak was raging in China but had not yet been declared a worldwide pandemic. As of Feb. 21, the Friday before the meeting, the United States had only 30 confirmed cases, according to data compiled by The Times. Biogen executives in Germany, Switzerland and Italy — where there were just 20 known cases — packed their bags.
Peter Bergethon, the head of digital and quantitative medicine at Biogen, went home to his wife, an infectious-disease doctor. On March 2, the following Monday, the company’s chief medical officer sent an email informing everyone who attended the leadership meeting that some people had fallen ill and telling them to contact a health care provider if they felt sick.Still, that same day, the company’s four top executives attended a huge health care conference hosted by the investment firm Cowen. At another Marriott in Boston, they held meetings in hotel rooms with potential investors.
That Tuesday, Biogen contacted the Massachusetts Department of Public Health and reported that about 50 employees in the Boston area and overseas had flulike symptoms. Biogen employees began showing up at the emergency room of Massachusetts General Hospital, demanding tests. They were told their cases didn’t satisfy the testing criteria at the time, since none had traveled to a hot spot or had known exposure to someone who had tested positive for COVID-19.